Hematological Malignancies
Phase II trial design BV in early favorable HL
cHL in CS I/II without RF* Age 18-75
Strategy B: Replacing Radiotherapy
Strategy A: Reducing Chemotherapy
4 x BV #
2 x AVD
20 Gy IS-RT
4 x BV #
* a) large mediastinal mass b) extranodal disease c) elevated ESR d) ≥3 nodal areas # to be discussed: 1.8 mg/kg every 3 weeks or 1.2 mg/kg every 2 weeks
Made with FlippingBook